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Epidermolysis bullosa acquisita (EBA) is an autoimmune skin blistering disease
characterized by IgG autoantibodies (aAb) against type VII collagen (COL7). The
mechanisms controlling the formation of such aAbs and their effector functions in the
skin tissue are incompletely understood. Here, we assessed whether the inhibitory IgG
Fc receptor, FcγRIIB, controls the development of autoimmune skin blistering disease
in an active model of EBA. For this purpose, we immunized congenic EBA-susceptible
B6.SJL-H2s (B6.s) and B6.s-Fcgr2b−/− mice with the immunodominant vWFA2 region
of COL7. B6.s-Fcgr2b−/− mice developed a strong clinical phenotype with 15 ± 3.3%
of affected body surface area at week 4. In contrast, the body surface area in B6.s
mice was affected to a maximum of 5% at week 6 with almost no disease signs
at week 4. Surprisingly, we already found strong but similar COL7-specific serum
IgG1 and IgG2b aAb production at week 2. Further, aAb and C3b deposition in
the skin of B6.s and B6.s-Fcgr2b−/− mice increased between weeks 2 and 6 after
vWFA2 immunization. Importantly, neutrophil skin infiltration and activation was much
stronger in B6s-Fcgr2b−/− than in B6.s mice and already present at week 2. Also, the
early aAb response in B6.s-Fcgr2b−/− mice was more diverse than in wt B6.s mice.
Reactive oxygen species (ROS) release from infiltrating neutrophils play a crucial role
as mediator of skin inflammation in EBA. In line, sera from B6.s and B6.s-Fcgr2b−/−
mice induced strong ROS release from bone marrow-neutrophils in vitro. In contrast
to the antibody-transfer-induced EBA model, individual targeting of FcγRIII or FcγRIV
decreased ROS release to 50%. Combined FcγR blocking abrogated ROS release from
BM neutrophils. Also, ROS release induced by COL7-specific serum IgG aAbs was
significantly higher using BM neutrophils from B6.s-Fcgr2b−/− than from B6.s mice.
Together, our findings identified FcγRIIB as a suppressor of skin inflammation in the
active EBA model through inhibition of early epitope spreading, protection from strong
early neutrophil infiltration to and activation of neutrophils in the skin and suppression of
FcγRIII activation by IgG1 aAbs which drive strong ROS release from neutrophils leading
to tissue destruction at the dermal-epidermal junction.
Keywords: Fcγ receptor, epidermolysis bullosa acquisita, autoimmunity, neutrophils, IgG, animal model,
pemphigoid disease
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INTRODUCTION
FcγRs are a heterogeneous receptor family. Aggregation by
IgG immune complexes (IC) results in the initiation of
activating or inhibitory signaling cascades. With the exception
of the inhibitory FcγRIIB, all other FcγRs trigger cellular
activation. FcγRs are predominantly expressed by innate immune
cells. The relative distribution of activating/inhibitory FcγR
expression sets the threshold of innate immune cell activation
through IgG ICs (1). FcγRs play an important role in the
host defense against pathogens as receptors for pathogen
phagocytosis. Further, they promote protective immunity against
pathogens (2).
In addition to their important and desirable role in immune
defense, FcγRs may also contribute to disease pathogenesis,
especially in autoimmune diseases. In this setting, aAbs activate
myeloid cells through FcγR aggregation after the formation
of soluble or tissue-bound ICs comprising their cognate auto-
antigens (3). Therefore, IC/FcγR interactions have become a
potential drug target for the treatment of aAb-mediated diseases
such as rheumatoid arthritis or pemphigoid diseases. More
specifically, IC/FcγR interactions can be blocked by modulating
Fc-glycosylation patterns (4, 5) or by competitive binding
of soluble FcγRIIB (sCD32, SM101) to IC (6, 7). Hence,
understanding FcγR biology has facilitated the drug development
in autoantibody-mediated diseases. This is of particular interest
for pemphigoid diseases, where high dose corticosteroids, often
associated with severe adverse events, form the backbone of the
therapeutic regimen (8, 9).
Due to the availability of a highly reproducible animal
model (10), the pemphigoid disease EBA has been relatively
well-studied in the past (11). In EBA, aAbs directed against
COL7, an integral structural protein of the skin, cause
chronic subepidermal blistering, a variable degree of cutaneous
inflammation and scaring, as well as organ damage at sites of
COL7 expression including the gastro-intestinal tract, eyes, and
larynx (12).
The generation of the autoimmune response in EBA depends
on B cells, dendritic cells and macrophages as antigen-presenting
cells, CD4+ T helper cells and neutrophils as the dominant
effector cells in skin lesions (13). At the molecular level,
formation of anti-COL7 humoral immune response is enhanced
by GM-CSF (14). The initial step in disease development is the
binding of anti-COL7 aAbs to their target antigen, which is
predominantly expressed in the skin. The formation of tissue-
bound IC in the skin drives the activation of the complement
system, a ß2-integrin-mediated migration of myeloid cells to
skin and subsequent production and release of proinflammatory
mediators including cytokines, chemokines and leukotrienes
(15–18). Within the skin, myeloid cells interact with the ICs.
In humans, this process depends on FcγRIIA and IIIB (19). In
a neonatal mouse model of EBA, induced by the intradermal
transfer of rabbit anti-mouse COL7 IgG, EBA development was
driven by FcγRIII activation on neutrophils (20). In contrast,
in an antibody-transfer model of EBA, activation FcγRIV on
neutrophils was identified as a crucial step for disease induction
(21). Absence of FcγRIIB expression was associated with a higher
disease score (21, 22).
These findings suggest that activating FcγRs drive disease
development during the effector phase using COL7-specific
rabbit IgG and that FcγRIIB protects from disease development
to some extent. Genetic association studies point toward
a possible contribution of FcγRs to pemphigoid disease
susceptibility. In humans, susceptibility to bullous pemphigoid
is associated with a gain in FCGR2C and loss of FCGR3B gene
copy numbers (23), as well as differences in the FCGR3A allotypes
(24). In mice, blister formation in response to immunization
with COL7 in an active model of EBA is linked to the H2s
haplotype (25). Further, some EBA-resistant C57BL/6j (B6.j)
mice developed disease symptoms when FcγRIIB-deficient mice
on the B6.j background were repeatedly immunized with a
COL7-GST fusion protein (26). Under these conditions, they
found that around 50% of B6.j-Fcgr2b−/− but none of the B6.j
mice developed a clinical phenotype, while all mice developed
aAbs which were deposited in the skin. Here, we aimed
to determine whether FcγRIIB controls the development of
autoimmune skin blistering disease in an active model of EBA.
For this purpose, we crossed FcγRIIB-deficient mice to the EBA-
susceptible inbred B6.s background (13, 27) and immunized
B6.s and B6.s-Fcgr2b−/− mice with the immunodominant von-
Willebrand-factor-A-like domain 2 (vWFA2) region of COL7
(13). Then, we assessed the impact of FcγRIIB on the disease-
permitting H2s haplotype on the formation of COL7-specific
IgG aAbs, their epitope specificity, and functional properties, i.e.,
recruitment of neutrophils into the skin and their activation by
activating FcγRs.
MATERIALS AND METHODS
Mice
B6.SJL-H2s C3c/1CyJ (B6.s), C57Bl/6J (B6.j) and Fcgr2b−/−
on the B6.SJL (B6.s-Fcgr2b−/−) or C57Bl/6J (B6.j-Fcgr2b−/−)
genetic background were bred and housed in a 12-h light-dark
cycle at the animal facility of the University of Lübeck. Mice
were killed by cervical dislocation and organs were harvested
after intraperitoneal administration of a mixture of ketamine
(100µg/g) and xylazine (15µg/g).
Immunization-Induced EBA Model
Mice were immunized as previously described with some
modifications (10, 26). Briefly, after anesthesia, B6.s wt and
B6.s-Fcgr2b−/− mice were immunized once with 60 µL of
1 mg/ml recombinant murine COL7 vWFA2 emulsified (1:1
mixture) in the non-ionic block copolymer adjuvant TiterMaxTM
(ALEXIS Biochemicals, Norcross, GA) into each of the hind
footpads. vWFA2 was produced after cloning of a commercially
synthesized codon (Mr. Gene, Regensburg, Germany) optimized
sequence in pTWIN (NEB, Frankfurt, Germany). In a second
step, proteins were expressed in E. coli ER2566 and purified
according to IMPACT
TM
-TWIN protocol (NEB) as described
(13). Subsequently, mice were evaluated for 6 weeks in 2-week
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intervals for the presence of skin lesions (i.e., erythema, blisters,
erosions, crusts, and alopecia). Disease severity was expressed
as percentage of body surface area affected by skin lesions.
Serum samples were collected every second week. Serum, ear
skin, and tail skin samples were obtained 2, 4, or 6 weeks after
immunization and prepared for histopathologic examination
and immunofluorescence (IF) microscopy. In accordance with
animal welfare regulations, individual mice were sacrificed, if
they lost more than 10% weight within 1 week and/or the
affected skin surface reached>25% of the total skin surface area.
Photographs were taken with standardized camera settings from
multiple angles.
Antibodies
For the antibody transfer-induced model, we used rabbit
anti-vWFA2 antibodies (20 mg/mL) produced as described
(28). For histology, we used AF647-labeled antibodies against
IgG (Jackson Immuno Research; 25µg/ml) or FITC-labeled
antibodies against C3b (MP Biomedicals; 55500; 66µg/mL).
Further, we used polyclonal goat anti-mouse IgG directed against
myeloperoxidase (MPO) (R&D Systems, AF3667, 0.2 mg/mL)
and the monoclonal rat anti-mouse IgG antibody RB6-8C5
against Ly6G (Abcam, ab25377, 0.1 mg/mL). As secondary
antibodies, we used goat anti rat IgG (H+L) labeled with
Alexa Fluor 594 (Thermo Fisher Scientific, Invitrogen, A-
11007, 2 mg/mL) or donkey anti goat IgG (H+L) labeled
with Alexa Fluor 488 (Thermo Fisher Scientific, Invitrogen,
A-11055, 2 mg/mL). Also, we used DAPI (4’,6-Diamidino-2-
Phenylindole, Dihydrochloride, Life Technologies; D3571, 5
mg/mL) for all immunofluorescence stainings. In addition, we
used monoclonal rat anti-mouse IgG2a directed against CD19
labeled with Alexa Fluor 647 (Biolegend, 115522, 0.5 mg/mL)
and monoclonal hamster anti-mouse IgG1 directed against
CD3 labeled with FITC (BD, 553062, 0.5 mg/mL). For flow
cytometric analysis, we used BV421-labeled antibodies against
FcγRI (Biolegend; 139309; 0.2 mg/mL); FITC-labeled antibodies
against FcγRIIB (provided by Falk Nimmerjahn; clone Ly17.2;
0.5 mg/mL), APC-labeled antibodies against FcγRIV (Biolegend;
149506; 0.2 mg/mL), APC-Cy7-labeled antibodies against Ly6G
(Biolegend; 127623; 0.2 mg/mL) and secondary PE-labeled anti-
goat antibodies (Santa Cruz biotechnology; sc-3857 0.4 mg/mL).
Unlabeled antibodies against FcγRIII (Thermofisher; PA5-47230;
0.2 mg/mL); and against FcγRIV (Biolegend; 149506; 0.2 mg/mL)
were used for blocking experiments.
Reactive Oxygen Species (ROS) Release
Assay
In this assay, intra- and extracellular ROS production
from neutrophils were measured using luminol-amplified
chemiluminescence after incubation with IC and controls,
respectively. Neutrophils were isolated from bone marrow
by flushing the femur and tibia with PBS using a 26G needle
and red blood cells were removed with red blood cell lysis
buffer (155mM NH4Cl, 10mM KHCO3, 0.1mM EDTA at pH
7.2). Neutrophils were transferred to and kept in RPMI1640
(Genaxxon bioscience; C4116.0500) containing 1% fetal calf
serum (PAA Cell Culture Company; A15-043) until use. For
FcγR blocking, we incubated neutrophils with anti-FcγRIII
(0.8µg/mL) and/or anti-FcγRIV (8.5µg/mL) for 1 h at 37◦C, 5%
CO2. Ninety-six-well microtiter plates (Greiner bio one; 655074)
were coated with 20µg/mL vWFA2 in PBS buffer. After washing
with PBS-Tween (0.5%), sera from immunized B6.s wt mice
were added in a 1:10 dilution for 1 h. After a second washing
step neutrophils (2 × 106/mL) with 5% of Luminol (Sigma
Aldrich; 123072-5G) were added to each well. The luminescence,
corresponding to the amount of liberated ROS in form of OH−,
O−2 , and H2O2 was measured for 1 h using a Fluostar Omega
ELISA reader (BMG Labtech) at an absorbance rate up to 3600
and an average measurement interval of 1 s at 37◦C.
Determination of COL7-Specific IgG Serum
Auto-Antibody Titers
Ninety-six-well plates were coated with vWFA2 (2.5µg/ml) in
0.05M sodium-carbonate buffer for 10min at room temperature.
After blocking with 1% BSA-PBS, sera from immunized mice
taken 2, 4, or 6 weeks after immunization were incubated
on the plate for 1 h. The sera were diluted 1:103, 1:104, and
1:105 in PBS. Then, HRP-coupled anti-mouse IgG (IgG1, IgG2b,
IgG2c, or IgG-total; 1:6000 in PBS) were added for 1 h. Finally,
50 µL of Trimethoprim (TMP) was added and samples were
measured on a Fluostar Omega (BMG Labtech) ELISA reader at
450 nm.
vWFA2 Epitope Mapping of Sera From
Immunized B6.s and B6.s-Fcgr2b−/− Mice
Ninety-six-well plates were coated with vWFA2-derived
polypeptides (2.5µg/ml). The peptides were generated by
peptides & elephants (Heringsdorf, German). Altogether, 19
20-mer peptides with 10 amino acid overlap (Table 1) were
generated. They were dissolved in 0.05M sodium-carbonate
buffer for epitope mapping for 10min at room temperature.
After blocking with 1% BSA-PBS, sera from immunized B6.s and
B6.s-Fcgr2b−/− mice were diluted 1:104 and incubated for 1 h.
Then, HRP anti-mouse was added for 1 h. Finally, 50 µL of TMB
were added and samples were measured on a Fluostar Omega
(BMG Labtech) at 450 nm.
IgG Auto-Antibody and C3b Deposition
Tissue-bound IgG aAb and C3b deposition was determined by
direct IF microscopy of frozen sections in TissueTek (Sakura;
Ref4583) using AF647-conjugated goat anti-mouse IgG (Jackson
Immuno Research; 25µg/mL), or FITC-conjugated goat anti-
mouse C3b (MP Biomedicals; 55500; 66µg/mL). Staining was
evaluated using the Keyence BZ-9000E microscope with the
BZII viewer and analyzer software. Intensity analysis was
performed with the ImageJ comparison tools and results were
compared by one-way ANOVA. First, we identified the basal
membrane in bright field setting and then measured the intensity
on the corresponding spot in the AF647 or FITC channel;
subsequently we repeated this process for the epidermis as
a negative control, where we found no specific IgG or C3
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TABLE 1 | vWFA2-derived polypeptides used for epitope mapping.
Name Sequence
Peptide 1 GRAMGACSH GPVDVVFLLHA
Peptide 2 GPVDVVFLLHA TRDNAHNAEA
Peptide 3 TRDNAHNAEA VRRVLERLVS
Peptide 4 VRRVLERLVS ALGPLGPQAA
Peptide 5 ALGPLGPQAA QVGLLTYSHR
Peptide 6 QVGLLTYSHR PSPLFPLNSS
Peptide 7 PSPLFPLNSS HDLGIILRKI
Peptide 8 HDLGIILRKI RDIPYVDPSG
Peptide 9 RDIPYVDPSG NNLGTAVTTA
Peptide 10 NNLGTAVTTA HRYLLASNAP
Peptide 11 HRYLLASNAP GRRQQVPGVM
Peptide 12 GRRQQVPGVM VLLVDEPLRG
Peptide 13 VLLVDEPLRG DILSPIREAQ
Peptide 14 DILSPIREAQ TSGLKVMALS
Peptide 15 TSGLKVMALS LVGADPEQLR
Peptide 16 LVGADPEQLR RLAPGTDPIQ
Peptide 17 RLAPGTDPIQ NFFAVDNGPG
Peptide 18 NFFAVDNGPG LDRAVSDLAV
Peptide 19 NGPG LDRAVSDLAV ALCQAA
Sequences shown in bold highlight overlapping sequences.
binding, and eventually calculated the difference between the
measured intensities.
Determination of FcγR Expression on Bone
Marrow Neutrophils
To identify BM neutrophils, freshly harvested lower extremities
were stored in PBS, flushed with PBS through 26G needles and
red blood cell lysis was performed with lysis buffer (155mM
NH4CL; 10mM KHCO3; 0.1mM EDTA; pH=7,22). First, we
set a gate in the FSC SSC blot on lymphocytes excluding debris
(Figure 6A).Within this gate, we identified neutrophils as Ly6G+
cells using APC-Cy7-labeled antibody against Ly6G (Biolegend;
127623; 0.7µg/mL). To determine activating and inhibitory FcγR
expression, the cell suspension was then stained with specific
FcγRIIB (1.7µg/mL), FcγRI, FcγRIII, FcγRIV (all 0.7µg/mL)
antibodies for 15min at 4◦C. Cells were washed and analyzed on
the BD LSRII cell analyzer. Results were analyzed via FlowJoV10
(Tree Star, Ashland, OR).
Assessment of MPO+, Ly6G+, CD3+, or
CD19+ Cells in Mouse Ear Tissue
We identified MPO+ or Ly6G+ cells by direct IF microscopy
of frozen ear sections in Tissue-Tek (Sakura, Ref4583) using
polyconal goat IgG antibodies directed against mouse MPO
(R&D Systems, AF3667) at a concentration of 2µg/mL or
monoclonal rat anti mouse Ly6G IgG (Abcam, ab25377, RB6-
8C5) at a concentration of 1µg/mL. Binding of the MPO or
Ly6G-specific Abs was detected using either goat anti rat IgG
(H+L) labeled with Alexa Fluor 594 (Thermo Fisher Scientific,
Invitrogen, A-11007, 2 mg/mL) or donkey anti goat IgG
(H+L) labeled with Alexa Fluor 488 (Thermo Fisher Scientific,
Invitrogen, A-11055, 2 mg/mL) at a concentration of 4µg/mL.
To detect CD19+ B cells or CD3+ T cells via IF microscopy
in frozen ear sections, we performed the following staining.
Sections were stained with monoclonal rat anti-mouse IgG2a
directed against CD19 labeled with Alexa Fluor 647 (Biolegend,
115522, 0,5 mg/mL) or monoclonal hamster anti-mouse IgG1
directed against CD3 labeled with FITC (BD, 553062, 0,5
mg/mL). Both antibodies were used at a concentration of
8,33µg/mL. MPO and Ly6G stainings were evaluated using
the EVOS M7000 imaging system (Thermo Fisher Scientific,
Germany) and Celleste imaging analysis software (Thermo Fisher
Scientific, Germany). CD3 staining was evaluated using the
Olymus Fluor 1000 (Olympus, Germany) and FV10-ASW 4.2
(Olympus, Germany). Cell counting and fluorescence intensity
analysis was performed with the ImageJ comparison tools. To
enumerate MPO+ or Ly6G+ cells, we evaluated 10 pictures each
with a size of 0.15 mm2 and 10 pictures for CD3+ and CD19+
with a size of 0.21 mm2 each.
Statistical Analysis
Data were analyzed with GraphPad Prism Version 8.0. All data
shown in the graphs are presented as mean values ± standard
error of the mean (SEM). All groups analyzed for ROS release
showed a normal distribution as tested by the Kolmogorov–
Smirnov test. Two group comparison were done via unpaired
Student’s t-test or Mann Whitney U-test. Comparisons between
multiple groups were done via non-parametric one-way ANOVA
and Dunn’s multiple comparisons as a post-hoc test. Differences
between groups were considered significant when the p-value was
<0.05 (∗p<0.05, ∗∗p<0.01, ∗∗∗p< 0.001).
RESULTS
B6.s-Fcgr2b−/− Mice Developed a Severe
Clinical Phenotype Early After
Immunization With COL7
B6.s wt and B6.s-Fcgr2b−/− were injected with vWFA2 together
with Titermax to induce experimental EBA. Mice were scored
as outlined in material and methods. We found that B6.s wt
mice developed clinical symptoms between weeks 4 and 6 after
vWFA2 immunization. In contrast, B6.s-Fcgr2b−/− mice showed
first clinical signs of skin blistering between weeks 2 and 4
after antigen administration. Importantly, the frequency of skin
lesions was significantly higher in B6.s-Fcgr2b−/− mice. The
affected body surface area in wt mice was 4.9 ± 2.1% but 23.1
± 5.7% in B6.s-Fcgr2b−/− mice 6 weeks after immunization
(Figure 1A). Already after 4 weeks, the affected body surface
area reached 15.0 ± 3.3% in B6.s-Fcgr2b−/− mice. At this time
point, we observed almost no lesions in the skin of B6.s wt mice.
Interestingly, lesions in wt mice at the early disease stage were
limited to the ears and the head neck region, whereas in FcγRIIB-
deficient mice extensive lesions occurred also on the torso and
the upper limbs (Figure 1B). Due to the fulminant disease
progression in mice lacking FcγRIIB, three mice needed to be
sacrificed already 4 weeks after the initiation of the experiment.
Such mice exceeded 25% of affected body surface area, which was
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FIGURE 1 | Disease development in B6.s-Fcgr2b−/− mice compared to B6.s wt controls. vWFA2 was injected at a dose of 60 µg/mouse s.c. into each of the hind
footpads of B6.s mice (n = 12) and B6.s-Fcgr2b−/− mice (n = 12). Animals were monitored for 6 weeks. They developed erosions and crusts around the eyes, snout,
ears, neck and torso. (A) Cumulative disease score of the affected body surface area between weeks 0 and 6 in B6.s-Fcgr2b−/− mice as compared with B6.s wt
controls. Statistical differences between wt and Fcgr2b−/− mice were determined by an unpaired t-test. Values shown are the mean ± SEM; n = 12 for each group.
(*p < 0.05; ***p < 0.001). (B) Representative pictures of non-immunized (upper row) and immunized (lower row, week 4) B6.s wt controls (left) and B6.s-Fcgr2b−/−
mice (right).
set as the threshold to abort the experiment. None of the B6.s wt
mice reached this criterion.
The Production of vWFA2-Specific IgG
Serum Auto-Antibodies Is Similar in B6.s
and B6.s-Fcgr2b−/− Mice
In search for mechanisms underlying the early disease
development in mice lacking FcγRIIB, we first determined
the vWFA2-specific serum IgG aAb titers in B6.s wt and
B6.s-Fcgr2b−/− mice 2, 4-, and 6-weeks post immunization.
We analyzed the total IgG (Figure 2A) as well as the IgG1
(Figure 2B), IgG2b (Figure 2C) and IgG2c (Figure 2D) aAb
subclasses. In both strains, we found significant amounts
of anti-vWFA2 specific IgG1 and IgG2 aAbs 2 weeks after
immunization, demonstrating that the generation of these aAbs
starts during the first 2 weeks after immunization. Importantly,
we observed no significant differences in the amount of IgG aAbs
produced in mice lacking FcγRIIB when compared to B6.s wt
mice (Figures 2A–D). Of note, the amount of vWFA2-specific
IgG2c aAbs was lower than that of IgG1 or IgG2b aAbs in the
two strains (Figure 2D). Taken together, the data show that the
absence of FcγRIIB has no obvious impact on the quality and the
quantity of IgG aAb production.
We next evaluated if differences in epitope specificity of the
IgG aAb response could explain the observed clinical differences.
For this purpose, we performed an epitope mapping with
19 overlapping 20-mer polypeptides spanning the entire NC1
domain of vWFA2 using the serum aAbs from B6.s wt and B6.s-
Fcgr2b−/− collected at weeks 2, 4, and 6. In week two, some
sera from B6.s wt and B6.s-Fcgr2b−/− mice both recognized an
N-terminal peptide (peptide 4) and a peptide in the middle of
vWFA2 (peptide 11). Interestingly, all sera from B6.s-Fcgr2b−/−
mice but none of the sera from B6.s wt mice recognized
an epitope within the C-terminal peptide 17. Further, some
sera from B6.s-Fcgr2b−/− mice recognized epitopes in peptides
adjacent to peptide 17, i.e., peptides 13–16 and peptide 18. Four
weeks after immunization the number of epitopes recognized
by the sera from B6.s wt mice increased markedly. Similar to
the sera from B6.s-Fcgr2b−/− mice, wt sera now recognized an
epitope within peptide 17 and in the C-terminal part of vWFA2.
Several of these epitopes overlapped with those recognized by
the sera from FcγRIIB mice. Interestingly, sera from both mouse
strains recognized an epitope within peptide 5. The epitope
pattern recognized by the sera from B6.s-Fcgr2b−/− mice was
similar between weeks 4 and 6 with a dominant binding to C-
terminal peptides and peptide 5 from the N-terminal part of
vWFA2. Sera taken 6 weeks after immunization from B6.s wt
mice showed a recognition pattern similar to that from B6.s-
Fcgr2b−/− mice, except that a few more epitopes within peptides
from the N-terminal half of vWFA2 were recognized (peptides 6,
7, and 9) (Figure 2E). Taken together, our findings demonstrate
that the early aAb response 2 weeks after immunization is
more diverse in B6.s-Fcgr2b−/− mice and already results in the
formation of IgG aAbs that recognize epitopes within the C-
terminal part of vWFA2. Importantly, several of these epitopes
are also immunodominant in B6.s wt mice, although at a later
time point (i.e., in weeks 4 and 6).
IgG Auto-Antibody and C3b Deposition at
the Dermal-Epidermal Junction Is Similar
in B6.s and B6.s-Fcgr2b−/− Mice
A prerequisite for the recruitment of effector cells to the
skin that drive the formation of blisters, is the deposition
of COL7-specific aAbs and the activation of complement at
the (DEJ) zone. To assess, if the higher disease score seen
in FcγRIIB deficient mice is associated with an increased IgG
antibody or complement deposition at the DEJ, we stained skin
samples taken 2, 4, or 6 weeks after vWFA2 immunization
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FIGURE 2 | Comparison of vWFA2-specific serum IgG levels and epitope mapping during the first 6 weeks after vWFA2 immunization. Course of vWFA2-specific (A)
total IgG, (B) IgG1, (C) IgG2b; and (D) IgG2c serum aAb levels. The IgG serum levels between B6.s wt and B6.s-Fcgr2b−/− mice were similar. n = 4/group and time
point. (E) Linear epitope mapping of vWFA2-specific total IgG using 20 amino acids long polypeptides of vWFA2 with an overlap of 10 amino acids. IgG peptide
binding was determined via ELISA. n ≥ 3/group and time point. The depicted frequencies (0, <20, <40, <80, and 100%) relate to the percent of sera in B6.s wt or
B6.s-Fcgr2b−/− mice that reacted with respective peptide.
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with IgG or C3b-specific antibodies. This was of particular
interest, as our epitope mapping showed a more diverse epitope
recognition using sera from B6.s-Fcgr2b−/− mice (Figure 2B).
As shown in Figures 3A,B, we found only minor IgG or C3b
deposition 2 or 4 weeks after disease initiation in both strains.
Disease-related IgG aAb and C3b deposition slightly increased 4
weeks after immunization in B6.s wt and B6.s-Fcgr2b−/− mice
(Figures 3A,B). However, we observed no significant differences
between the two strains. Six weeks after antigen immunization,
the deposition of IgG aAb and C3b increased markedly in
both strains (Figure 3B), but still we observed no significant
differences between the two strains. Collectively, our findings
identified no major differences in IgG or C3b deposition during
the first 6 weeks after disease initiation in B6.s wt or B6.s-
Fcgr2b−/− mice. These findings suggest that differences in IgG
aAb or C3b deposition during the first 6 weeks after vWFA2
immunization do not account for the differences in disease
development that we have observed between B6.s wt and B6.s-
Fcgr2b−/− mice. Surprisingly, the very high disease score that
we found 6 weeks after immunization in B6.s-Fcgr2b−/− mice
seems to be independent of altered IgG aAb or C3b deposition
at the DEJ.
FcγRIIB-Deficient Mice Suffer From Strong
Early Neutrophil Recruitment Into the Skin
Associated With Strong Neutrophil
Activation
Recruitment and activation of neutrophils to the DEJ is an
important effector mechanism that drives blister formation in
EBA (29). Therefore, we determined the number of Ly6G+ cells
and the expression of MPO within the hole ear skin cut. First,
we already observed the recruitment of Ly6G+ neutrophils into
the skin of B6.s and B6.s-Fcgr2b−/− mice 2 weeks after vWFA2
immunization (Figures 4A–D, Supplementary Figure 1).
Importantly, the number of neutrophils was significantly higher
in B6.s-Fcgr2b−/− than in B6.s mice (32.5 ± 23 vs. 88.7 ±
42, Figure 4D, left panel). After 4 weeks of immunization
the number of neutrophils further increased in the skin of
B6.s-Fcgr2b−/− mice but not in B6.s mice (24.1 ± 9 vs. 134.8 ±
29, Figure 4D, middle panel). After 6 weeks of immunization
the number of neutrophils in the skin of B6.s-Fcgr2b−/− mice
somewhat decreased. Here, we need to take into account that 4–6
weeks after vWAF2 immunization, several B6.s-Fcgr2b−/− mice
had reached the termination criteria and had to be sacrificed.
The number of neutrophils in B6.s wt mice increased 6 weeks
after immunization as compared to the 4 week time point and
reached numbers comparable to that of B6.s-Fcgr2b−/− mice
(70.3± 41 vs. 91.1± 26, Figure 4D, right panel).
Since not only the infiltration of the neutrophils into the
skin, but also their activation plays a decisive role in disease
development, we also determined the expression of MPO in
the skin (Figures 4E–H, Supplementary Figure 1). Here, the
difference in MPO expression between wild-type and FcyRIIB-
deficient animals was even more striking than that observed for
neutrophil infiltration. We found strong MPO signals in B6.s-
Fcgr2b−/− but not in B6.s wt animals already in week 2 after
immunization (Figure 4H). This signal increased toward week 4
in B6.s-Fcgr2b−/−,while it was still very low in B6.s wtmice. Only
6 weeks after immunization, we observed a strong MPO signal in
B6.s wt mice, which was ever higher than that observed in B6.s-
Fcgr2b−/− mice. Again, the data in the B6.s-Fcgr2b−/− mice are
biased toward the phenotypically less affected animals. Together,
these findings demonstrate a stronger and earlier recruitment
of neutrophils into the skin of B6.s-Fcgr2b−/− mice that were
activated to produce high amounts of MPO when compared to
B6.s wt mice. Next, we analyzed the infiltration of CD3+ cells
into the skin, as previous publications have shown that T cells
make an important contribution to the pathogenesis of EBA (30)
(Figures 5A–D, Supplementary Figure 1). As compared with
neutrophils, the infiltration with T cells was much lower. In B6.s
wt mice we observed no significant differences between vWFA2-
immunized and titermax-only treated mice (titermax: 1.4 ± 1,
w2: 2.5 ± 2, w4: 2.7 ± 1.25, w6: 1.1 ± 0.8, Figure 5B). In B6.s-
Fcgr2b−/− mice, we noticed a decrease of CD3+ cells in the
skin over time (titermax: 3.9 ± 2.3, w2: 2.6 ± 2, w4: 1.3 ± 1.1,
w6: 1.4 ± 1.2, Figures 5C,D). In contrast to T cells, we did not
find any B cells by direct IF in the skin cryosections. This is in
accordance with previous studies, in which autoreactive B cells
were almost exclusively found in the peripheral lymph nodes
in the immunization-induced EBA mouse model (21, 31) (data
not shown).
Neutrophils From FcγRIIB- Deficient Mice
Are More Sensitive to FcγRIII- and
FcγRIV-Driven ROS Release by
vWFA2-Specific IgG Auto-Antibodies
Themost important effector function of neutrophils in the skin is
the release of ROS through aggregation of activating FcγRs (22).
Thus, we tested the potential of the sera from immunized wt and
B6.s-Fcgr2b−/− mice to induce ROS release. For this purpose, we
used bone marrow neutrophils. In a first step, we determined the
expression of activating FcγRs and the inhibitory FcγRIIB. We
found that Ly6G+ bone marrow neutrophils are expressing the
activating FcγRs FcγRIII (98.4%) and FcγRIV (86%), whereas
FcγRI is barely detectable. Similar to FcγRIII and FcγRIV,
FcγRIIB was strongly expressed on 90% of all bone marrow
neutrophils (Figures 6A,B). In the antibody transfer model of
EBA, an exclusive role for FcγRIV activation has been shown
regarding the induction of ROS release by COL7-specific rabbit
IgG (21). In mice, FcγRIV activation is largely independent from
FcγRIIB counterbalance (32). In contrast, FcγRIII activation by
IgG1 antibodies heavily depends on FcγRIIB expression, as IgG1
antibodies bind to FcγRIIB and FcγRIII with similar affinity (1).
In the second step, we thus aimed to determine, which
FcγRs are activated by the sera from immunized B6.s wt and
B6.s-Fcgr2b−/− mice to drive ROS release from bone marrow
neutrophils. For this purpose, we stimulated bone marrow
neutrophils with sera from wt mice. As shown in Figure 6C,
wt sera induced a strong peak within the first 10min after
administration. Thereafter, ROS production steadily declined
during the next 50min. FcγRIII blockade did not change the
kinetic of the ROS release. However, the total amount of
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FIGURE 3 | Direct immunofluorescence staining showing the deposition of IgG aAbs and C3b in perilesional biopsies of ear skin from B6.s wt and B6.s-Fcgr2b−/−
mice. (A) Linear deposits of murine IgG and C3b along the basal membrane zone. Representative immunofluorescence pictures of skin sections were taken at weeks
2, 4, and 6. Red = IgG aAb deposition; Green = C3b deposition. (B) Quantitative evaluation of IgG aAb and C3 deposition in B6.s wt and B6.s-Fcgr2b−/− mice.
Microscopic pictures were analyzed via ImageJ software. The staining intensity of the basal membrane zone was measured, and a reference area of the epidermis
was subtracted from it defining the intensity value MFI[1] for each sample in three different high-power fields; Data are shown as scattered dot plot with mean and
standard error of the mean. Differences between groups were analyzed by non-parametric one-way ANOVA with post-hoc Dunn’s multiple comparisons test,
(*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).
generated ROS decreased to 67.9 ± 4.5% of that induced in the
presence of the isotype control. In contrast, the ROS release was
delayed when FcγRIV was targeted. Further, the amount of ROS
released from the bone marrow neutrophils decreased to 42.4 ±
5.3% of that induced by the B6.s wt serum in the presence of
the isotype control. The joint blocking of FcγRIII and FcγRIV
abrogated the wt serum-induced ROS release from bone marrow
neutrophils. In fact, the amount of ROS production (13.8± 2.0%)
reached the level of unstimulated neutrophils (Figure 6D and
data not shown). In a similar experimental setup, we tested the
potential of rabbit anti-mouse COL7-antibodies to induce ROS
in the presence of absence of blocking antibodies against FcγRIII
and/or FcγRIV. Confirming previous findings (21), we found that
vWFA2-specific rabbit IgG, that are used in antibody-transfer
model of EBA, drive ROS release through exclusive activation
of FcγRIV, whereas FcγRIII does not seem to play any role
(Figure 6E).
Finally, we compared the ROS-inducing potential of anti-
vWFA2 IgG aAbs from B6.s wt or B6.s-Fcgr2b−/− mice
using bone marrow neutrophils from either B6.j wt or B6.j-
Fcgr2b−/− mice. We found a markedly and significantly
increased ROS production induced by sera from either B6.s wt
or B6.s-FcγRIIB-deficient mice, when we used bone marrow
neutrophils from B6.j-Fcgr2b−/− mice instead of neutrophils
from B6.j wt mice (Figure 6F). These findings demonstrate
a critical role for FcγRIIB in controlling IgG aAb -driven
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FIGURE 4 | Strong early migration of Ly6G+ neutrophils to and MPO induction in the skin of B6.s-Fcgr2b−/− but not B6.s wt mice. (A) Presence of Ly6G+ neutrophils
in the skin of B6.s wt and B6.s-Fcgr2b−/− mice. Representative immunofluorescence staining of ear sections taken 2, 4, and 6 weeks after immunization with
(Continued)
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FIGURE 4 | vWAF2 antigen. Red = Ly6G+ neutrophils; Blue = DAPI. (B,C) Quantitative evaluation of Ly6G+ neutrophils in 0.15 mm2 sections of B6.s wt (B) and
B6.s-Fcgr2b−/− mice (C) during the 6 weeks observation period at week 2, 4, and 6. Titermax Control: representative staining of skin sections from B6.s wt and
Fcgr2b−/− mice treated with Titermax (D). Comparison of the Ly6G+ neutrophil numbers in the skin of B6.s and B6.s-Fcgr2b−/− mice at week 2 (left panel), 4 (middle
panel), and 6 (right panel). Pictures were analyzed via ImageJ and Celleste software. (E) Presence of MPO+ signals in the skin of B6.s wt and B6.s-Fcgr2b−/− mice.
Representative immunofluorescence staining of ear sections taken 2, 4, and 6 weeks after immunization with vWAF2 antigen. Green = MPO+ signals; Blue = DAPI.
(F,G) Quantitative evaluation of MPO+ signals in 0.15 mm2 sections of B6.s wt (G) and B6.s-Fcgr2b−/− mice (G) during the 6 weeks observation period at week 2, 4,
and 6. Control: Representative staining of skin sections from B6.s wt and Fcgr2b−/− mice treated with Titermax (D). Comparison of the MPO+ signals numbers in the
skin of 6.s and B6.s-Fcgr2b−/− mice at week 2 (left panel), 4 (middle panel), and 6 (right panel). Data in (B–D) and (F–H) are shown as scatter blot with mean ± SEM.
Differences between week 2, 4, and 6 in (B,C,F,G) were analyzed by non-parametric one-way ANOVA. Differences between B6.s and B6.s-Fcgr2b−/− mice (D,H)
were evaluated by unpaired Student’s t-test (*p < 0.05, **p < 0.01, ****p < 0.0001).
FIGURE 5 | CD3+ numbers in the skin of B6.s wt and B6.s-Fcgr2b−/− mice. (A) Presence of CD3+ T cells in the skin of B6.s wt and B6.s-Fcgr2b−/− mice 2, 4, and
6 weeks after immunization with vWAF2 antigen. Pictures show immunofluorescence staining from ear sections (green = CD3+ T cells; blue = DAPI). Positive signals
are indicated by arrows. (B,C) Quantitative evaluation of CD3+ T cells in 0.21 mm2 sections of B6.s wt (B) and B6.s-Fcgr2b−/− mice (C) during the 6 weeks
observation period at weeks 2, 4, and 6..(D) Comparison of the CD3+ T cells numbers in skin of B6.s and B6.s-Fcgr2b−/− mice at week 2 (left panel), 4 (middle panel),
and 6 (right panel). Pictures were analyzed via ImageJ. Data in b-d are shown as scatter blot with mean ± SEM. Differences between week 2, 4, and 6 in (B,C) were
analyzed by non-parametric one-way ANOVA test. Differences between B6.s and B6.s-Fcgr2b−/− mice (D) were evaluated by unpaired Student’s t-test (**p < 0.01).
ROS release from neutrophils suggesting that the main
effect underlying the increased phenotype that we observed
in B6.s-Fcgr2b−/− mice results from insufficient control of
FcγRIIB-deficient neutrophil activation by IgG aAbs through
FcγRIII activation.
DISCUSSION
EBA is a rare autoimmune skin disease, with an incidence of
0.08–0.5 new cases per million per year, in which autoantibodies
to COL7 bind to the DEJ and induce blister formation on the
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FIGURE 6 | FcγR expression in bone marrow neutrophils and impact of vWFA2-specific IgG auto-antibodies on ROS release. (A) Flow cytometric analysis of FcγR
expression in Ly6G+ bone marrow neutrophils. First, bone marrow cells were pregated using the FSC/SSC to exclude cell debris, residual erythrocytes, and
lymphocytes, then singlets were excluded via FSC-A/FSC-H gating. In the last step, we gated on Ly6Ghi positive neutrophils, which were either stained for FcγRIII and
FcγRIV expression (upper panel) or FcγRI and FcγRIIB expression (lower panel). (B) Quantitative assessment of FcγR expression in bone marrow neutrophils. High
expression of FcγRIIB, FcγRIII, and FcγRIV (90.7 ± 1.4%; 98.4 ± 4.4%, and 86.43 ± 9.9%, respectively) but almost no FcγRI expression (0,96% ± 0,6%) in Ly6G+
neutrophils; n = 6/group, scatter blot with mean ± SEM. (C) ROS release from bone marrow neutrophils in response to sera from immunized wt B6.s mice (week 4) in
the presence or absence of individual or combined FcγRIII/FcγRIV targeting. The graph is representative of 9 independent experiments. (D) Impact of FcγRIII and/or
FcγRIV targeting on immune serum-driven ROS release from wt bone marrow neutrophils.; n = 25/group. Data are shown as scatter blot with mean ± SEM. The
immune sera were from immunized wt B6.s mice (week 4). A non-parametric One-way ANOVA was used to determine significant differences and post-hoc Dunn’s
multiple comparison test to assess differences between individual groups (*p < 0.05; **p < 0.001; ****p < 0.0001). (E) Impact of FcγRIII and/or FcγRIV targeting on
immune serum-driven ROS release from wt bone marrow neutrophils. The immune sera were taken from rabbits immunized with vWFA2, n = 6/group. Data shown
are scattered dot blot with mean ± SEM (*p < 0.05; **p < 0.01) (F) Potency of sera from B6.s and B6.s-Fcgr2b−/− mice to induce ROS release from B6.s wt (green)
or B6.s-Fcgr2b−/− (blue) neutrophils. Neutrophils from B6.j-Fcgr2b−/− mice produced more ROS than those from wt B6.s mice in response to sera from either B6.s
or B6.s-Fcgr2b−/− mice. n = 10 / group. Data shown are scattered dot blot with mean ± SEM. Unpaired Mann–Whitney test was used to determine significant
differences between groups (**p < 0.01).
skin and erosions on the mucus membranes (33–35). Such aAbs
against COL7 are detectable in the basement membrane and
in the serum. Despite advancements in the understanding of
the pathogenesis, effective treatment still remains a challenge
(35). Experimental models of EBA support the idea that binding
of aAbs to COL7 mediates inflammation and triggers blister
formation (18, 36). In an antibody-transfer model (passive
model) of EBA, using rabbit-derived antibodies against COL7,
it was shown that these antibodies activate the complement
system, resulting in the release of pro-inflammatory cytokines
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and chemokines, and neutrophil recruitment into the skin (18).
In this model neutrophils interact with the rabbit anti-mouse
COL7 IC exclusively via FcγRIV, resulting in the release of ROS
and proteolytic enzymes (18, 21, 37). The different subclasses
of IgGs differ in their ability to bind to distinct FcγRs and
their potency activate them. Further, the relative distribution of
activating FcγRs and the inhibitory FcγR, FcγRIIB, determines
the magnitude of IgG-driven immune cell activation. Despite
their undisputed beneficial role in translating antibody-responses
into cellular responses, they are also involved in the pathogenesis
of various autoimmune bullous diseases. Clearly, FcγRs play an
essential role in the pathogenesis of EBA (38). The main goal of
this study was to assess whether the inhibitory FcγR, FcγRIIB,
controls the development of autoimmune skin blistering disease
in the active model of EBA, in which we immunized mice with
the immunodominant vWFA2 region of COL7.
To the best of our knowledge, this is the first report on the
role of FcγRIIB in an active model of EBA, in which congenic
FcγRIIB-deficient and wt mice with the same disease-permitting
H2s haplotype (B6.s background) have been compared side-
by-side regarding the impact of FcγRIIB on the B and the
effector cell responses. Sitaru et al. used FcγRIIB-deficient
mice on the EBA-resistant C57BL/j (B6.j) background (H2b
haplotype) and immunized the mice repeatedly (4 x) with
GST-tagged COL7. Under these conditions, they found that
around 50% of B6.j-Fcgr2b−/− but none of the B6.j mice
developed a clinical phenotype, while all mice developed aAbs
which were deposited in the skin (26). Importantly, GST-
peptide tag coupled to the murine fibronectin III–like domains
(FNIII) 7 and 8 of COL7 (termed mCOL7C) modulates
the mCOL7C-specific plasma cell response and the induction
of EBA (13, 31). The immunization scheme that we used
in our study drives disease development independent from
immune responses to other antigens, i.e., GST. Also, the
vWFA2 domain of COL7 is an immunodominant epitope in
humans (13, 39), which is why we used this part of the COL7
protein without GST-tag for immunization. Thus, the active
EBA model used in this study is based on a more specific
immune response to a more EBA-relevant protein fragment
of COL7.
In a first step, we analyzed the role of the inhibitory FcγRIIB
in controlling the disease and its impact on aAb formation, since
this is the only FcγR expressed on B lymphocytes (40). We
found that B6.s-Fcgr2b−/− mice suffer from earlier disease onset
and faster disease progression resulting in more severe disease
phenotype than their B6.s wt counterparts. Interestingly, B6.s wt
mice show first signs of the disease betweenweek 4 and 6, whereas
FcγRIIB-deficient mice were already affected between week 2 and
4 after immunization. Even more striking was the fact that all
wt mice reached the endpoint of the experiment after 6 weeks,
while some of the FcγRIIB-deficient mice had to be sacrificed,
as they reached the pre-defined abortion criterium of more than
25% affected body-surface area. This finding of an important
contribution of FcγRIIB to disease onset and severity is in
agreement with previous reports that have linked polymorphisms
in FcγRIIB with autoimmune diseases including SLE (41, 42),
rheumatoid arthritis (43), anti-GBM diseases (44), IC-mediated
alveolitis (45), and collagen-induced arthritis (46).
To further delineate the role of FcγRIIB in EBA development,
we characterized the antibody response in B6.s wt and B6.s-
Fcgr2b−/− mice during the course of the disease to determine
whether the lack of FcγRIIB would affect the vWFA2-specific
IgG response. In the past, it was shown that polymorphisms in
the promoter and regulatory region of FCGRIIB are associated
with a reduced expression of this receptor, which caused a
higher susceptibility for autoimmune diseases (47–49) suggesting
an important role for FcγRIIB in controlling B cell activity to
prevent autoimmune responses. This was confirmed by a study
using B cell-specific conditional FcγRIIB-deficient mice, in which
the absence of FcγRIIB on B cells increased the humoral response
after T-dependent immunization and aggravated disease severity
in chicken collagen-induced arthritis (50). In contrast, the
humoral immune response decreased in the same arthritis model,
when mice were used that overexpress FcγRIIB on B cells (51).
However, Yilmaz-Elis et al. (52) were not able to reproduce
the increased levels of aAbs. In light of these findings, we
determined in the present study the aAb response in B6.s wt
and B6.s-Fcgr2b−/− mice during the course of EBA. To our
surprise, we found no differences in the levels of vWFA2-specific
IgG aAbs during the course of the disease. B6.s wt and B6.s-
Fcgr2b−/− mice showed the same kinetic and amount of IgG
aAb production, suggesting that the early disease onset and the
severe clinical phenotype in B6.s-Fcgr2b−/− mice were caused by
other mechanisms.
During an autoimmune response, tissue damage can lead to
the priming of self-reactive T or B cells, regardless of the initial
insult resulting in a phenomenon known as epitope spreading.
Thus, we tested whether the severe lesions with massive tissue
destruction of the skin observed in FcγRIIB-deficient mice would
lead to strong epitope spreading and/or IgG aAbs produced in
FcγRIIB-deficient mice would recognize epitopes different from
those recognized by IgG aAbs fromB6.s wtmice as ameasure that
might account for the aggravated phenotype in B6.s-Fcgr2b−/−
mice. In epitope-mapping experiments, we observed several
immunodominant epitopes that were recognized by IgG aAbs
from B6.s wt and FcγRIIB deficient sera [i.e., (5, 13, 17)].
However, B6.s-Fcgr2b−/− mice showed an accelerated target
evolution. All sera from B6.s-Fcgr2b−/− mice but none from
B6.s wtmice recognized the immunodominant epitope in peptide
17 already 2 weeks after vWFA2 immunization. Further, <20%
of FcγRIIB- but none of the B6.s wt sera reacted with the
immunodominant epitope in peptide 13 at this time point. Also
<20% of the B6.s-Fcgr2b−/− sera already recognized several
peptides that overlapped with peptides 13 (i.e., peptide 14)
or 17 (i.e., peptides 16 and 18) in this early stage of disease
development, while B6.s wt mice reached the highest diversity
in their aAb response only in week 6 (11 targets, 40–100%).
These findings suggest a direct effect of FcγRIIB on B cells for
antibody profiling or an indirect effect through increased antigen
presentation on APCs such as skin DCs, eventually resulting in
a more severe inflammation at the DEJ. Clearly, the early disease
onset with a higher magnitude of inflammation in the absence
of FcγRIIB is associated with strong antibody spreading before
disease onset.
Interestingly, we found almost no (week 2) or only weak
(week 4) IgG aAb deposition and consecutive complement
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deposition in the early stage of the disease in both mouse
strains although IgG aAb serum titers were already high 2 weeks
after immunization. However, 6 weeks after immunization we
found markedly increased levels of IgG aAb and complement
deposition at the DEJ, but—as for the IgG serum titers—there was
no detectable difference between wt and B6.s-Fcgr2b−/− mice.
Based on these findings we concluded that the massive clinical
phenotype that we observed in FcγRIIB-deficient mice was not
caused by an aggravated IgG aAb or C3b deposition, since there
was no detectable difference compared to the wt mice.
Next, we investigated whether the absence of FcγRIIB affects
the recruitment and activity of neutrophil granulocytes into the
skin. Interestingly, we already found strong neutrophil migration
into the skin of B6.s-Fcgr2b−/−mice 2 weeks after immunization,
when aAb deposition at the DEJ was low. At week 4, the number
of neutrophils was even higher and exceeded by far the number of
neutrophils in B6.s wtmice. In week 6, neutrophil skin infiltration
was high in B6.s wt and B6.s-Fcgr2b−/− mice. This observation
matches the strong disease phenotype in B6.s-Fcgr2b−/− that
we had observed in week 4 and the delayed disease onset in
B6.s wt mice at week 6. This view was supported by the MPO
expression as an indicator of neutrophil activity. The strongMPO
expression in B6.s-Fcgr2b−/−mice in weeks 2 and 4 paralleled the
high number of number of neutrophils. Even more striking, we
found at best minor MPO expression in the skin of B6.s wt mice
suggesting minor activation of the recruited neutrophils. These
findings suggest that FcγRIIB activation controls the recruitment
and the activation of neutrophils into the skin. In future studies,
it will be important to delineate the mechanisms underlying the
FcγRIIB-mediated regulation of neutrophil homing into the skin
and their activation in the skin tissue. Clearly, FcγRIIB expression
controls FcγRIII-driven activation of neutrophils. Interestingly,
in the antibody-transfer model of EBA, in which COL7-specific
Abs from rabbits are injected into mice, the activation of
neutrophils and the development of skin lesions is exclusively
mediated through FcγRIV (21). Based on our findings that
vWFA2-immunized B6.s wt and B6.s-Fcgr2b−/− mice produced
IgG1, IgG2b and IgG2 aAbs, which were deposited at the DEJ
and resulted in distinct recruitment and neutrophil activation,
we aimed to determine the individual contribution of each IgG
isotype and the corresponding FcγR to disease development. For
this purpose, we conducted in vitro experiments, in which we
induced ROS release from bone marrow neutrophils using sera
from B6.s wt mice. The B6.j wt neutrophils that we used as ROS
producers were treated with antibodies to block either FcγRIII,
FcγRIV individually or in combination. In these experiments,
we showed that the blockade of FcγRIV was not sufficient to
completely block the ROS release by bone marrow neutrophils.
In contrast to the findings with rabbit anti-mouse COL7 Abs,
the sole blockade of FcγRIII was almost as efficient in reducing
ROS release from neutrophils as FcγRIV targeting. Importantly,
only the combined targeting of FcγRIII and FcγRIV reduced
ROS release to the baseline level. This finding is of major
importance, as it demonstrates that not only IgG2b/c but also
IgG1 aAbs can drive neutrophil activation in the active EBA
model. Obviously, the passive EBAmodel using rabbit IgG Abs is
biased toward FcγRIV-mediated neutrophil activation due to the
fact that rabbit IgG seems to exclusively bind to FcγRIV in the
murine systems. Our findings demonstrate that IgG aAbs raised
in response to vWFA2 are heterogenous and comprise Abs of
the IgG1 and the IgG2 subtype, both of which drive neutrophil
activation. Importantly, IgG1-mediated FcγRIII activation is
controlled by FcγRIIB co-expression, whereas IgG2c-driven
neutrophil activation by FcγRIV is largely independent of
FcγRIIB co-expression (53). We found that stimulation of bone
marrow neutrophils from FcγRIIB-deficient mice with sera
from either B6.s wt or B6s.FcγRIIB-deficient mice immunized
with vWFA2 resulted in a markedly higher ROS release than
stimulation of bone marrow neutrophils from FcγRIIB-sufficient
wt mice. These data confirm the importance of FcγRIIB as an
important negative regulator of IgG aAb-driven ROS release
from neutrophils in active experimental EBA,most likely induced
through IgG1 aAbs that trigger FcγRIII. Future studies that
aim to determine the immune mechanisms underlying EBA
development should take this difference into account.
The current standard EBA treatment comprising
corticosteroids, rituximab, intravenous immunoglobulins
(IVIG), colchicine and other broadly immune suppressive
drugs is associated with several severe side effects. Clearly,
an unmet need exists for more specific therapies. Our
data suggest that controlling FcγRIIB or targeting FcγRIII
and FcγRIV might serve as a novel treatment strategy in
EBA patients.
In summary, we found that FcγRIIB is crucially involved
in the development of skin blistering in an immunization-
induced mouse model of EBA. It results in an early disease
onset and the development of a very severe disease phenotype
through regulation of the immune response at several levels.
First, FcγRIIB suppresses early epitope spreading and strong
production of IgG aAbs that recognize an immunodominant
epitope within the C-terminus of the NC-1 domain of vWFA2.
Secondly, FcγRIIB protects from strong early neutrophil
infiltration to and activation of neutrophil granulocytes
in the skin. Thirdly, FcγRIIB is critical to counterbalance
FcγRIII activation by IgG1 aAbs which drive enhanced ROS
release from neutrophils leading to tissue destruction at the
DEJ. Our findings that FcγRIII and FcγRIV drive disease
development in active EBA should be considered in future
studies that aim to delineate the immunemechanisms underlying
EBA development.
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